Page last updated: 2024-10-17

creatine and Diabetes Mellitus, Type 2

creatine has been researched along with Diabetes Mellitus, Type 2 in 67 studies

Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.

Research Excerpts

ExcerptRelevanceReference
"Twenty-two type 2 DM patients with microalbuminuria were treated with 50-100 mg/day of Losartan for 6 months."9.12Effects of losartan on urinary secretion of extracellular matrix and their modulators in type 2 diabetes mellitus patients with microalbuminuria. ( Berard, L; Hak, D; Khan, S; Ma, GM; Ni, LS; Penner, B; Shen, GX; Woo, V; Zhu, F, 2006)
"Twenty-two type 2 DM patients with microalbuminuria were treated with 50-100 mg/day of Losartan for 6 months."5.12Effects of losartan on urinary secretion of extracellular matrix and their modulators in type 2 diabetes mellitus patients with microalbuminuria. ( Berard, L; Hak, D; Khan, S; Ma, GM; Ni, LS; Penner, B; Shen, GX; Woo, V; Zhu, F, 2006)
"The model highlighted a relevant contribution of inflammation (glycosylation pattern and HDL) and muscle (creatinine and creatine) in the development of type 2 diabetes as independent factors of hyperglycemia."4.31NMR-based metabolomic profiling identifies inflammation and muscle-related metabolites as predictors of incident type 2 diabetes mellitus beyond glucose: The Di@bet.es study. ( Amigó, N; Guardiola, M; Masana, L; Ozcariz, E; Rehues, P; Ribalta, J; Rojo-Martínez, G; Valdés, S, 2023)
"Patients with chronic kidney disease and type 2 diabetes have a higher risk of developing pneumonia as well as an increased risk of severe COVID-19-associated adverse events and mortality."3.11Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis. ( Agarwal, R; Ahlers, C; Anker, SD; Brinker, M; Filippatos, GS; Joseph, A; Lambelet, M; Lawatscheck, R; Pitt, B; Rossing, P; Ruilope, LM, 2022)
"Treatments of diabetic nephropathy (DN) delay the onset of end-stage renal disease."2.73Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. ( Bolton, WK; Degenhardt, TP; Khalifah, RG; McGill, JB; Schotzinger, RJ; Williams, ME, 2007)
"Diabetic nephropathy is the leading cause of end-stage renal disease."2.70Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. ( Brenner, BM; Cooper, ME; de Zeeuw, D; Keane, WF; Mitch, WE; Parving, HH; Remuzzi, G; Shahinfar, S; Snapinn, SM; Zhang, Z, 2001)
" Inhibiting SSAO activity by natural agents might reduce the potential adverse effects of creatine metabolism in population of T2DM."2.66Beneficial Impact of Semicarbazide-Sensitive Amine Oxidase Inhibition on the Potential Cytotoxicity of Creatine Supplementation in Type 2 Diabetes Mellitus. ( Deng, Y; Papukashvili, D; Rcheulishvili, N, 2020)
"In patients with type 2 diabetes, BP variability contributes to the formation of CI through a pro-inflammatory mechanism (osteopontin), leading to impaired brain vascularization in general, white matter structure, and hippocampal metabolism."1.72[Blood pressure variability and neuroplasticity in patients with type 2 diabetes mellitus]. ( Kudlay, DA; Matveeva, MV; Samoilova, YG, 2022)
"The study outcome was incident type 2 diabetes, defined as a fasting plasma glucose ≥7."1.62Plasma creatine and incident type 2 diabetes in a general population-based cohort: The PREVEND study. ( Bakker, SJL; Connelly, MA; de Boer, RA; Douwes, RM; Dullaart, RPF; Flores-Guerrero, JL; Franssen, CFM; Garcia, E; Groothof, D; Kema, IP; Post, A; Schutten, JC; Swarte, JC; Wallimann, T, 2021)
"This study included 119 patients with type 2 diabetes mellitus (T2DM) and 76 non-diabetic subjects matched by sex and age."1.51Shortened mean erythrocyte age in female patients with type 2 diabetes mellitus. ( Ijima, H; Inada, S; Iwasaka, T; Jinnouchi, H; Koga, M; Okumiya, T; Ono, Y, 2019)
"Eighty six patients with Type 2 diabetes mellitus (T2DM) were enrolled for this study."1.43[Correlation between cognitive impairment and diabetic nephropathy in patients with Type 2 diabetes mellitus]. ( Niu, H; Shen, J; Shi, X; Wang, R; Wang, S; Wu, J; Yang, H; Zhang, Y; Zhou, S, 2016)
"Diabetic retinopathy was assessed by fundus photography and graded using modified Airlie House classification."1.38Systemic soluble tumor necrosis factor receptors 1 and 2 are associated with severity of diabetic retinopathy in Hispanics. ( Chen, YD; Cui, J; Guo, X; Ipp, E; Klein, BE; Klein, R; Kuo, JZ; Rotter, JI, 2012)
"Documented diabetic nephropathy prevalence showed marked variation across practices (range 0-100%) and was significantly negatively correlated with diabetes list size, albumin creatinine ratio testing rates and renin-angiotensin-aldosterone system blockade use and positively correlated with exception reporting rates."1.36Identifying additional patients with diabetic nephropathy using the UK primary care initiative. ( Cardwell, CR; Fogarty, DG; Hunter, SJ; Kee, F; Magee, GM; Murphy, MC; Savage, G, 2010)
"Patients with type 2 diabetes and major depression (n=20) were scanned along with patients with diabetes alone (n=24) and healthy controls (n=21) on a 1."1.34Measurement of brain metabolites in patients with type 2 diabetes and major depression using proton magnetic resonance spectroscopy. ( Ajilore, O; Binesh, N; Darwin, C; Haroon, E; Kumar, A; Kumaran, S; Miller, J; Mintz, J; Thomas, MA, 2007)
"However, diabetic patients with ESRD secondary to dNP were significantly younger than those with vNP."1.33Rate of decline of GFR and progression of vascular disease in type 2 diabetic patients with diabetic or vascular nephropathy during the last three years before starting dialysis therapy. ( Biesenbach, G; Janko, O; Pieringer, H; Schmekal, B, 2006)
"Forty-seven patients with one decade of type 2 diabetes and 51 non-diabetic control subjects were studied."1.30Evaluation of plasma cystatin C as a marker for glomerular filtration rate in patients with type 2 diabetes. ( Harmoinen, AP; Kouri, TT; Lehtimäki, TJ; Pasternack, AI; Rantalaiho, V; Turjanmaa, VM; Wirta, OR, 1999)
"He had no disorders that could induce microangiopathic hemolytic anemia other than diabetic microangiopathy."1.29Case report: diabetic microangiopathic hemolytic anemia and thrombocytopenia with antiphospholipid syndrome. ( Daidoh, H; Ishizuka, T; Morita, H; Suwa, T; Takeda, N; Yasuda, K, 1996)
"The high prevalence of small LDL in diabetic nephropathy was also observed even when hypertriglyceridemic or hypertensive subjects were excluded from each group."1.29High prevalence of small LDL particles in non-insulin-dependent diabetic patients with nephropathy. ( Adachi, M; Ebara, T; Hirano, T; Kurokawa, M; Nagano, S; Naito, H; Yoshino, G, 1996)
" In the healthy individuals, urinary guanidinoacetic acid excretion increased 5-fold by 2 h after dosing (15."1.28Clinical test of renal guanidinoacetic acid metabolism by oral citrulline and creatine loading. ( Kadono, K; Tetsutani, T; Yamaguchi, T; Yasunaga, K, 1992)

Research

Studies (67)

TimeframeStudies, this research(%)All Research%
pre-19902 (2.99)18.7374
1990's6 (8.96)18.2507
2000's18 (26.87)29.6817
2010's29 (43.28)24.3611
2020's12 (17.91)2.80

Authors

AuthorsStudies
Mancini de Sousa, M1
Nakata, MTK1
Baldini, CES1
de Oliveira-Sales, EB1
Boim, MA1
Martimbianco, ALC1
Maquigussa, E1
Matveeva, MV2
Samoilova, YG2
Kudlay, DA2
Ijima, H2
Hiratani, K1
Jinnnouchi, H1
Ono, Y2
Kameyama, M1
Okumiya, T2
Koga, M2
Jang, SY1
Jung, Y1
Lee, DH1
Hwang, GS1
Pitt, B1
Agarwal, R1
Anker, SD1
Ruilope, LM1
Rossing, P1
Ahlers, C1
Brinker, M1
Joseph, A1
Lambelet, M1
Lawatscheck, R1
Filippatos, GS1
Ozcariz, E1
Guardiola, M1
Amigó, N1
Rojo-Martínez, G1
Valdés, S1
Rehues, P1
Masana, L1
Ribalta, J1
Ding, K1
Li, Z1
Lu, Y1
Sun, L2
Papukashvili, D1
Rcheulishvili, N1
Deng, Y1
Post, A1
Groothof, D1
Schutten, JC1
Flores-Guerrero, JL1
Swarte, JC1
Douwes, RM1
Kema, IP1
de Boer, RA1
Garcia, E1
Connelly, MA1
Wallimann, T1
Dullaart, RPF1
Franssen, CFM1
Bakker, SJL1
Morita, S1
Inai, Y1
Minakata, S1
Kishimoto, S1
Manabe, S1
Iwahashi, N1
Ino, K1
Ito, Y1
Akamizu, T1
Ihara, Y1
Solis, MY1
Artioli, GG3
Gualano, B5
Wu, GY1
Zhang, Q1
Wu, JL1
Jing, L1
Tan, Y1
Qiu, TC1
Zhao, J1
Gazdzinski, SP1
Gaździńska, AP1
Orzeł, J1
Redlisz-Redlicki, G1
Pietruszka, M1
Mojkowska, A1
Pacho, RA1
Wylezol, M1
Inada, S1
Jinnouchi, H1
Iwasaka, T1
Zhou, Y1
Qi, C1
Li, S1
Shao, X1
Mou, S1
Ni, Z1
Medrano Navarro, AL1
Justel Enríquez, A1
Alameda Serrano, J1
Blasco Lamarca, Y1
Sáenz Abad, D1
Gimeno Orna, JA1
Fried, PJ1
Pascual-Leone, A1
Bolo, NR1
Lin, Y1
Zhou, J1
Sha, L1
Li, Y1
Qu, X1
Liu, L1
Chen, H1
An, Z1
Wang, Y2
Sun, C1
Zhang, M1
Sun, X1
Zhang, Z2
Meng, Q1
Chen, J1
Ma, X1
Geng, H1
Ohkuma, T1
Fujii, H1
Iwase, M1
Ogata-Kaizu, S1
Ide, H1
Kikuchi, Y1
Idewaki, Y1
Jodai, T1
Hirakawa, Y1
Nakamura, U1
Kitazono, T1
Hajek, T1
Calkin, C1
Blagdon, R1
Slaney, C1
Alda, M1
Ma, Y1
Huang, D1
Zhang, R1
Xu, S1
Feng, S1
Zhao, C1
Luo, Q1
He, F1
Peng, F1
Xia, X1
Huang, F1
Yu, X1
Furuyama, JK1
Nagarajan, R1
Roberts, CK1
Lee, CC1
Hahn, TJ1
Thomas, MA2
Rodriguez-Poncelas, A1
Miravet-Jiménez, S1
Casellas, A1
Barrot-De La Puente, JF1
Franch-Nadal, J1
López-Simarro, F1
Mata-Cases, M1
Mundet-Tudurí, X1
Shi, X1
Zhang, Y1
Niu, H1
Wang, R1
Shen, J1
Zhou, S1
Yang, H1
Wang, S1
Wu, J1
Achilles, EI1
Maus, V1
Fink, GR1
Maintz, D1
van Eimeren, T1
Mpotsaris, A1
Pinto, CL1
Botelho, PB1
Pimentel, GD1
Campos-Ferraz, PL1
Mota, JF1
Simsek, IB1
Artunay, O1
Heikkilä, O1
Lundbom, N1
Timonen, M1
Groop, PH1
Heikkinen, S1
Mäkimattila, S1
Tiehuis, A1
van der Meer, F1
Mali, W1
Pleizier, M1
Biessels, GJ1
Kappelle, J1
Luijten, P1
Rocic, B2
Bajuk, NB1
Rocic, P2
Weber, DS1
Boras, J1
Lovrencic, MV1
Elley, CR1
Robinson, E1
Kenealy, T1
Bramley, D1
Drury, PL1
Xia, JF1
Hu, P1
Liang, QL1
Zou, TT1
Wang, YM1
Luo, GA1
DE Salles Painneli, V1
Roschel, H3
Neves, M1
De Sá Pinto, AL1
Da Silva, ME2
Cunha, MR2
Otaduy, MC3
Leite, Cda C2
Ferreira, JC2
Pereira, RM1
Brum, PC1
Bonfá, E2
Lancha, AH3
de Salles Painelli, V2
Lugaresi, R2
Dorea, E1
Lima, FR1
Seguro, AC1
Shimizu, MH1
Sapienza, MT1
da Costa Leite, C1
Lancha Junior, AH1
Zhao, LC1
Zhang, XD1
Liao, SX1
Gao, HC1
Wang, HY1
Lin, DH1
Magee, GM1
Hunter, SJ1
Cardwell, CR1
Savage, G1
Kee, F1
Murphy, MC1
Fogarty, DG1
Znaor, A1
Weber, D1
Vučić Lovrenčić, M1
Painelli de Salles, V1
Queiroz, AC1
Artioli, G1
Kuo, JZ1
Guo, X1
Klein, R1
Klein, BE1
Cui, J1
Rotter, JI1
Ipp, E1
Chen, YD1
Alves, CR1
de Siqueira-Filho, MA1
Carvalho, CR1
Goto, A1
Marre, M1
Garcia Puig, J1
Kokot, F1
Fernandez, M1
Jermendy, G1
Opie, L1
Moyseev, V1
Scheen, A1
Ionescu-Tirgoviste, C1
Saldanha, MH1
Halabe, A1
Williams, B1
Mion, D1
Ruiz, M1
Hermansen, K1
Tuomilehto, J1
Finizola, B1
Pozza, G1
Chastang, C1
Ollivier, JP1
Amouyel, P1
Asmar, R1
Rosenbaum, P1
Gimeno, SG1
Sanudo, A1
Franco, LJ1
Ferreira, SR1
Wihler, C1
Schäfer, S1
Schmid, K1
Deemer, EK1
Münch, G1
Bleich, M1
Busch, AE1
Dingermann, T1
Somoza, V1
Baynes, JW1
Huber, J1
Tseng, CH1
Tseng, CP1
Tai, TY1
Chong, CK1
Op't Eijnde, B1
Jijakli, H1
Hespel, P1
Malaisse, WJ1
Biesenbach, G1
Schmekal, B1
Pieringer, H1
Janko, O1
Ajilore, O1
Haroon, E1
Kumaran, S1
Darwin, C1
Binesh, N1
Mintz, J1
Miller, J1
Kumar, A1
Kim, CS1
Sohn, EJ1
Kim, YS1
Jung, DH1
Jang, DS1
Lee, YM1
Kim, DH1
Kim, JS1
Woo, V1
Ni, LS1
Hak, D1
Berard, L1
Zhu, F1
Khan, S1
Ma, GM1
Penner, B1
Shen, GX1
Williams, ME1
Bolton, WK1
Khalifah, RG1
Degenhardt, TP1
Schotzinger, RJ1
McGill, JB1
Wang, H1
Meng, QH1
Gordon, JR1
Khandwala, H1
Wu, L1
Srivastava, PM1
Calafiore, P1
Macisaac, RJ1
Patel, SK1
Thomas, MC1
Jerums, G1
Burrell, LM1
Modi, S1
Bhattacharya, M1
Sekhri, T1
Rana, P1
Tripathi, RP1
Khushu, S1
Morita, H1
Suwa, T1
Daidoh, H1
Takeda, N1
Ishizuka, T1
Yasuda, K1
Perfetto, F1
Tarquini, R1
de Leonardis, V1
Piluso, A1
Lombardi, V1
Tarquini, B1
Hirano, T1
Naito, H1
Kurokawa, M1
Ebara, T1
Nagano, S1
Adachi, M1
Yoshino, G1
Harmoinen, AP1
Kouri, TT1
Wirta, OR1
Lehtimäki, TJ1
Rantalaiho, V1
Turjanmaa, VM1
Pasternack, AI1
Brenner, BM1
Cooper, ME1
de Zeeuw, D1
Keane, WF1
Mitch, WE1
Parving, HH1
Remuzzi, G1
Snapinn, SM1
Shahinfar, S1
Zywiec, J1
Grzeszczak, W1
Pierzchała, K1
Kadono, K1
Yamaguchi, T1
Tetsutani, T1
Yasunaga, K1
Matsumoto, E1
Matsumoto, G1
Ooshima, A1
Kikuoka, H1
Bessho, H1
Miyamura, K1
Nanjo, K1
Dullaart, RP1
Roelse, H1
Sluiter, WJ1
Doorenbos, H1
Spesivtseva, VG1
Mamaeva, GG1
Starosel'tseva, LK1
Kozlova, EG1

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Event-driven Phase 3 Study to Investigate the Safety and Efficacy of Finerenone, in Addition to Standard of Care, on the Progression of Kidney Disease in Subjects With Type 2 Dia[NCT02540993]Phase 35,734 participants (Actual)Interventional2015-09-17Completed
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Event-driven Phase 3 Study to Investigate Efficacy and Safety of Finerenone on the Reduction of Cardiovascular Morbidity and Mortality in Subjects With Type 2 Diabetes Mellitus a[NCT02545049]Phase 37,352 participants (Actual)Interventional2015-09-17Completed
Efficacy and Safety of Creatine Supplementation Combined With Exercise Training in Type 2 Diabetic Patients[NCT00992043]28 participants (Actual)Interventional2009-10-31Completed
Open, Randomized, Unicenter Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease[NCT04626323]Phase 260 participants (Anticipated)Interventional2021-05-25Recruiting
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes Mellitus and Nephropathy[NCT00308347]Phase 31,513 participants (Actual)Interventional1996-05-31Completed
SGLT-2 Inhibitors in Prevention of Post-procedural Renal and Cardiovascular Complications aFter PCI Among Patients With Diabetes Mellitus and Coronary Artery Disease: a Prospective, Randomized, Pilot Study (SAFE-PCI)[NCT05037695]Phase 440 participants (Anticipated)Interventional2021-07-21Recruiting
Determinants of Diabetic Nephropathy in American Indians[NCT01878045]141 participants (Actual)Observational2013-11-07Suspended (stopped due to This study is on a temporary Administrative Hold pending further discussion for NIDDK and Tribal Leadership.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

All-cause Hospitalization

Count of participants and time from randomization to the first occurrence of a hospitalization event were evaluated. Number of participants with the event is reported as descriptive result and hazard ratio is reported as statistical analysis. (NCT02540993)
Timeframe: From randomization up until the first occurrence of the hospitalization due to any cause, or censoring at the end of study, with an average of 32 months

InterventionParticipants (Count of Participants)
Finerenone1263
Placebo1321

All-cause Mortality

Count of participants and time from randomization until death due to any cause were evaluated. Number of participants with outcome death is reported as descriptive result and hazard ratio is reported as statistical analysis. Number of participants with outcome death reported here includes deaths occurred after randomization until the end of the study visit. Deaths after end of study visit are not included in this table. (NCT02540993)
Timeframe: From randomization up until death due to any cause, or censoring at the end of the study visit, with an average of 32 months

InterventionParticipants (Count of Participants)
Finerenone219
Placebo244

Change in Urinary Albumin-to-creatinine Ratio (UACR) From Baseline to Month 4

First morning void urine samples were collected to evaluate the urinary albumin-to-creatinine ratio (UACR). Month 4 was the visit closest to day 120 within a time window of 120 ± 30 days after randomization. If no measurements were available in this time window, the participant was excluded from this analysis. Ratio of UACR at Month 4 to UACR at baseline is reported as the change. (NCT02540993)
Timeframe: From baseline up until Month 4

InterventionRatio (Least Squares Mean)
Finerenone0.655
Placebo0.952

The First Occurrence of the Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke, or Hospitalization for Heart Failure

Count of participants and time from randomization to the first occurrence of the key secondary cardiovascular (CV) composite outcome, CV death, non-fatal myocardial infarction (MI), non-fatal stroke, or hospitalization for heart failure were evaluated. Number of participants with the outcome event is reported as descriptive result and hazard ratio is reported as statistical analysis. (NCT02540993)
Timeframe: From randomization up until the first occurrence of the key secondary CV composite endpoint, or censoring at the end of the study, with an average of 32 months

InterventionParticipants (Count of Participants)
Finerenone367
Placebo420

The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease in eGFR of ≥57% From Baseline Over at Least 4 Weeks, or Renal Death

Count of participants and time from randomization to the first occurrence of the secondary renal composite outcome, onset of kidney failure, a sustained decrease in eGFR of ≥57% from baseline over at least 4 weeks, or renal death were evaluated. Number of participants with the outcome event is reported as descriptive result and hazard ratio is reported as statistical analysis. (NCT02540993)
Timeframe: From randomization up until the first occurrence of the composite primary endpoint, or censoring at the end of the study, with an average of 32 months

InterventionParticipants (Count of Participants)
Finerenone252
Placebo326

The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease of eGFR ≥40% From Baseline Over at Least 4 Weeks, or Renal Death

Count of participants and time from randomization to the first occurrence of the primary renal composite outcome, onset of kidney failure, a sustained decrease of eGFR ≥40% from baseline over at least 4 weeks, or renal death were evaluated. Number of participants with the outcome event is reported as descriptive result and hazard ratio is reported as statistical analysis. (NCT02540993)
Timeframe: From randomization up until the first occurrence of the primary renal composite endpoint, or censoring at the end of the study, with an average follow-up time of 32 months

InterventionParticipants (Count of Participants)
Finerenone504
Placebo600

All-cause Hospitalization

Number of participants with first occurrence of a hospitalization event were reported as descriptive result. (NCT02545049)
Timeframe: From randomization up until the first occurrence of the hospitalization due to any cause, or censoring at the end of study, with an average study duration of 41 months

InterventionParticipants (Count of Participants)
Finerenone1573
Placebo1605

All-cause Mortality

Number of participants with death due to any cause were reported as descriptive result. Number of participants with outcome death reported here includes deaths occurred after randomization until the end of the study visit. Deaths after end of study visit are not included in this table. (NCT02545049)
Timeframe: From randomization up until death due to any cause, or censoring at the end of the study, with an average study duration of 41 months

InterventionParticipants (Count of Participants)
Finerenone333
Placebo370

Change in Urinary Albumin-to-creatine Ratio (UCAR) From Baseline to Month 4

First morning void urine samples were collected to evaluate the urinary albumin-to-creatinine ratio (UACR). Month 4 was the visit closest to day 120 within a time window of 120 ± 30 days after randomization. If no measurements were available in this time window, the participant was excluded from this analysis. Ratio of UACR at Month 4 to UACR at baseline is reported as the change. (NCT02545049)
Timeframe: From baseline up until Month 4

InterventionRatio (Least Squares Mean)
Finerenone0.624
Placebo0.922

The First Occurrence of the Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non Fatal Stroke, or Hospitalization for Heart Failure.

Number of participants with the first occurrence of the primary cardiovascular (CV) composite outcome, CV death, non-fatal myocardial infarction (MI), non-fatal stroke, or hospitalization for heart failure were reported as descriptive result. (NCT02545049)
Timeframe: From randomization up until the first occurrence of the CV composite endpoint, or censoring at the end of the study, with an average study duration of 41 months.

InterventionParticipants (Count of Participants)
Finerenone458
Placebo519

The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease in eGFR of ≥57% From Baseline Over at Least 4 Weeks, or Renal Death

Number of participants with first occurrence of the renal composite outcome, onset of kidney failure, a sustained decrease in eGFR of ≥57% from baseline over at least 4 weeks, or renal death were reported as descriptive result. (NCT02545049)
Timeframe: From randomization up until the first occurrence of the renal composite endpoint, or censoring at the end of the study, with an average study duration of 41 months

InterventionParticipants (Count of Participants)
Finerenone108
Placebo139

The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease of eGFR ≥40% From Baseline Over at Least 4 Weeks, or Renal Death.

Number of participants with first occurrence of the composite endpoint of onset of kidney failure, a sustained decrease of eGFR ≥40% from baseline over at least 4 weeks, or renal death were reported as descriptive result. (NCT02545049)
Timeframe: From randomization up until the first occurrence of the renal composite endpoint, or censoring at the end of the study, with an average study duration of 41 months.

InterventionParticipants (Count of Participants)
Finerenone350
Placebo395

Reviews

5 reviews available for creatine and Diabetes Mellitus, Type 2

ArticleYear
Creatine Supplementation in Type 2 Diabetic Patients: A Systematic Review of Randomized Clinical Trials.
    Current diabetes reviews, 2022, Volume: 18, Issue:3

    Topics: Blood Glucose; Creatine; Diabetes Mellitus, Type 2; Dietary Supplements; Glyburide; Humans; Hypoglyc

2022
Beneficial Impact of Semicarbazide-Sensitive Amine Oxidase Inhibition on the Potential Cytotoxicity of Creatine Supplementation in Type 2 Diabetes Mellitus.
    Molecules (Basel, Switzerland), 2020, Apr-27, Volume: 25, Issue:9

    Topics: Adipokines; Amine Oxidase (Copper-Containing); Caffeine; Copper; Creatine; Diabetes Mellitus, Type 2

2020
Potential of Creatine in Glucose Management and Diabetes.
    Nutrients, 2021, Feb-09, Volume: 13, Issue:2

    Topics: Animals; Creatine; Diabetes Mellitus, Type 2; Dietary Supplements; Exercise; Glucose; Glucose Transp

2021
Changes in cerebral metabolites in type 2 diabetes mellitus: A meta-analysis of proton magnetic resonance spectroscopy.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2017, Volume: 45

    Topics: Aspartic Acid; Brain; Case-Control Studies; Choline; Creatine; Diabetes Mellitus, Type 2; Humans; In

2017
Creatine supplementation and glycemic control: a systematic review.
    Amino acids, 2016, Volume: 48, Issue:9

    Topics: Animals; Carbohydrate Metabolism; Creatine; Diabetes Mellitus, Type 2; Dietary Supplements; Glucose;

2016

Trials

12 trials available for creatine and Diabetes Mellitus, Type 2

ArticleYear
Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis.
    JAMA network open, 2022, 10-03, Volume: 5, Issue:10

    Topics: Albumins; Anti-Inflammatory Agents; COVID-19; Creatine; Diabetes Mellitus, Type 2; Diabetic Nephropa

2022
Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis.
    JAMA network open, 2022, 10-03, Volume: 5, Issue:10

    Topics: Albumins; Anti-Inflammatory Agents; COVID-19; Creatine; Diabetes Mellitus, Type 2; Diabetic Nephropa

2022
Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis.
    JAMA network open, 2022, 10-03, Volume: 5, Issue:10

    Topics: Albumins; Anti-Inflammatory Agents; COVID-19; Creatine; Diabetes Mellitus, Type 2; Diabetic Nephropa

2022
Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis.
    JAMA network open, 2022, 10-03, Volume: 5, Issue:10

    Topics: Albumins; Anti-Inflammatory Agents; COVID-19; Creatine; Diabetes Mellitus, Type 2; Diabetic Nephropa

2022
Diabetic Nephropathy Can Be Treated with Calcium Dobesilate by Alleviating the Chronic Inflammatory State and Improving Endothelial Cell Function.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2018, Volume: 51, Issue:3

    Topics: Aged; Albuminuria; Anti-Inflammatory Agents; Calcium Dobesilate; Chronic Disease; Creatine; Cross-Se

2018
Comparison of antihyperglycemic effects of creatine and metformin in type II diabetic patients.
    Clinical and investigative medicine. Medecine clinique et experimentale, 2009, Dec-01, Volume: 32, Issue:6

    Topics: Blood Glucose; Creatine; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic

2009
Creatine in type 2 diabetes: a randomized, double-blind, placebo-controlled trial.
    Medicine and science in sports and exercise, 2011, Volume: 43, Issue:5

    Topics: Blood Glucose; Blotting, Western; Creatine; Diabetes Mellitus, Type 2; Dietary Supplements; Double-B

2011
Creatine supplementation does not impair kidney function in type 2 diabetic patients: a randomized, double-blind, placebo-controlled, clinical trial.
    European journal of applied physiology, 2011, Volume: 111, Issue:5

    Topics: Creatine; Diabetes Mellitus, Type 2; Dietary Supplements; Double-Blind Method; Female; Humans; Kidne

2011
Comparison of antihyperglycemic effects of creatine and glibenclamide in type II diabetic patients.
    Wiener medizinische Wochenschrift (1946), 2011, Volume: 161, Issue:21-22

    Topics: Adult; Blood Glucose; C-Peptide; Creatine; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Gl

2011
Creatine supplementation does not augment muscle carnosine content in type 2 diabetic patients.
    Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme, 2011, Volume: 36, Issue:5

    Topics: Body Mass Index; Creatine; Diabetes Mellitus, Type 2; Dietary Supplements; Double-Blind Method; Exer

2011
Creatine-induced glucose uptake in type 2 diabetes: a role for AMPK-α?
    Amino acids, 2012, Volume: 43, Issue:4

    Topics: AMP-Activated Protein Kinases; Antigens, CD; Biopsy; Creatine; Diabetes Mellitus, Type 2; Double-Bli

2012
Effect of indapamide SR on microalbuminuria--the NESTOR study (Natrilix SR versus Enalapril Study in Type 2 diabetic hypertensives with micrOalbuminuRia)--rationale and protocol for the main trial.
    Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 2003, Volume: 21, Issue:1

    Topics: Adult; Aged; Albuminuria; Clinical Protocols; Creatine; Delayed-Action Preparations; Diabetes Mellit

2003
Effects of losartan on urinary secretion of extracellular matrix and their modulators in type 2 diabetes mellitus patients with microalbuminuria.
    Clinical and investigative medicine. Medecine clinique et experimentale, 2006, Volume: 29, Issue:6

    Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Coagulation Factors; Blood

2006
Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy.
    American journal of nephrology, 2007, Volume: 27, Issue:6

    Topics: Adolescent; Adult; Aged; Creatine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Ne

2007
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
    The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12

    Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre

2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
    The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12

    Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre

2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
    The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12

    Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre

2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
    The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12

    Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre

2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
    The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12

    Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre

2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
    The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12

    Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre

2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
    The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12

    Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre

2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
    The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12

    Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre

2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
    The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12

    Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre

2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
    The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12

    Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre

2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
    The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12

    Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre

2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
    The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12

    Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre

2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
    The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12

    Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre

2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
    The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12

    Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre

2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
    The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12

    Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre

2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
    The New England journal of medicine, 2001, Sep-20, Volume: 345, Issue:12

    Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre

2001

Other Studies

50 other studies available for creatine and Diabetes Mellitus, Type 2

ArticleYear
[Blood pressure variability and neuroplasticity in patients with type 2 diabetes mellitus].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2022, Volume: 122, Issue:3

    Topics: Blood Pressure; Blood Pressure Monitoring, Ambulatory; Choline; Creatine; Diabetes Mellitus, Type 2;

2022
[Blood pressure variability and brain neuroimaging in patients with type 2 diabetes].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2022, Volume: 122, Issue:5

    Topics: Blood Pressure; Brain; Brain Diseases; Choline; Creatine; Diabetes Mellitus, Type 2; Humans; Neuroim

2022
Measurement of erythrocyte creatine might be useful for diagnosing latent hemolysis.
    Clinical biochemistry, 2022, Volume: 107

    Topics: Anemia, Hemolytic; Blood Glucose; Creatine; Diabetes Mellitus, Type 2; Erythrocytes; Glycated Hemogl

2022
NMR-based metabolomic analysis of human plasma to examine the effect of exposure to persistent organic pollutants.
    Chemosphere, 2022, Volume: 307, Issue:Pt 4

    Topics: Cholesterol; Creatine; Creatinine; Diabetes Mellitus, Type 2; Environmental Pollutants; Formates; Hu

2022
NMR-based metabolomic profiling identifies inflammation and muscle-related metabolites as predictors of incident type 2 diabetes mellitus beyond glucose: The Di@bet.es study.
    Diabetes research and clinical practice, 2023, Volume: 202

    Topics: Creatine; Creatinine; Diabetes Mellitus, Type 2; Glucose; Humans; Inflammation; Magnetic Resonance S

2023
Efficacy and safety assessment of mineralocorticoid receptor antagonists in patients with chronic kidney disease.
    European journal of internal medicine, 2023, Volume: 115

    Topics: Bayes Theorem; Cardiovascular Diseases; Creatine; Diabetes Mellitus, Type 2; Diabetic Nephropathies;

2023
Plasma creatine and incident type 2 diabetes in a general population-based cohort: The PREVEND study.
    Clinical endocrinology, 2021, Volume: 94, Issue:4

    Topics: Blood Glucose; Creatine; Diabetes Mellitus, Type 2; Female; Humans; Insulin Resistance; Male; Middle

2021
Quantification of serum C-mannosyl tryptophan by novel assay to evaluate renal function and vascular complications in patients with type 2 diabetes.
    Scientific reports, 2021, 01-21, Volume: 11, Issue:1

    Topics: Biomarkers; Chromatography, Liquid; Creatine; Cystatin C; Diabetes Mellitus, Type 2; Diabetic Angiop

2021
Intragastric balloon therapy leads to normalization of brain magnetic resonance spectroscopic markers of diabetes in morbidly obese patients.
    NMR in biomedicine, 2018, Volume: 31, Issue:9

    Topics: Adipose Tissue; Body Mass Index; Body Weight; Brain; Creatine; Diabetes Mellitus, Type 2; Female; Ga

2018
Shortened mean erythrocyte age in female patients with type 2 diabetes mellitus.
    Journal of clinical laboratory analysis, 2019, Volume: 33, Issue:2

    Topics: Aged; Blood Glucose; Case-Control Studies; Creatine; Diabetes Mellitus, Type 2; Erythrocytes; Female

2019
Total and cardiovascular mortality risk according to KDIGO guidelines classification in type 2 diabetic patients.
    Medicina clinica, 2019, 10-11, Volume: 153, Issue:7

    Topics: Adult; Albuminuria; Analysis of Variance; Cardiovascular Diseases; Cause of Death; Chi-Square Distri

2019
Diabetes and the link between neuroplasticity and glutamate in the aging human motor cortex.
    Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology, 2019, Volume: 130, Issue:9

    Topics: Aged; Aged, 80 and over; Aging; Aspartic Acid; Creatine; Diabetes Mellitus, Type 2; Female; Glucose;

2019
Metabolite differences in the lenticular nucleus in type 2 diabetes mellitus shown by proton MR spectroscopy.
    AJNR. American journal of neuroradiology, 2013, Volume: 34, Issue:9

    Topics: Aged; Aged, 80 and over; Aspartic Acid; Biomarkers; Choline; Corpus Striatum; Creatine; Diabetes Mel

2013
Brain metabolite changes in patients with type 2 diabetes and cerebral infarction using proton magnetic resonance spectroscopy.
    The International journal of neuroscience, 2014, Volume: 124, Issue:1

    Topics: Aged; Aspartic Acid; Blood Glucose; Brain; Cerebral Infarction; Choline; Creatine; Diabetes Mellitus

2014
Association between sleep duration and urinary albumin excretion in patients with type 2 diabetes: the Fukuoka diabetes registry.
    PloS one, 2013, Volume: 8, Issue:11

    Topics: Aged; Albuminuria; Creatine; Diabetes Mellitus, Type 2; Female; Humans; Japan; Male; Middle Aged; Re

2013
Type 2 diabetes mellitus: a potentially modifiable risk factor for neurochemical brain changes in bipolar disorders.
    Biological psychiatry, 2015, Feb-01, Volume: 77, Issue:3

    Topics: Adult; Aspartic Acid; Bipolar Disorder; Brain; Creatine; Cross-Sectional Studies; Diabetes Mellitus,

2015
[Simultaneous determination of four common nonprotein nitrogen substances in urine by high performance liquid chromatography].
    Se pu = Chinese journal of chromatography, 2013, Volume: 31, Issue:11

    Topics: Chromatography, High Pressure Liquid; Creatine; Creatinine; Diabetes Mellitus, Type 2; Humans; Limit

2013
Establishing HbA1c -mean blood glucose formulae for patients on continuous ambulatory peritoneal dialysis.
    Diabetic medicine : a journal of the British Diabetic Association, 2014, Volume: 31, Issue:7

    Topics: Adult; Blood Glucose; Creatine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephr

2014
A pilot validation of multi-echo based echo-planar correlated spectroscopic imaging in human calf muscles.
    NMR in biomedicine, 2014, Volume: 27, Issue:10

    Topics: Adult; Bone Marrow; Choline; Creatine; Diabetes Mellitus, Type 2; Echo-Planar Imaging; Extracellular

2014
Prevalence of diabetic retinopathy in individuals with type 2 diabetes who had recorded diabetic retinopathy from retinal photographs in Catalonia (Spain).
    The British journal of ophthalmology, 2015, Volume: 99, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Creatine; Cross-Sectional Studies; Diabetes Mellitus,

2015
[Correlation between cognitive impairment and diabetic nephropathy in patients with Type 2 diabetes mellitus].
    Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2016, Volume: 41, Issue:2

    Topics: Adult; Aspartic Acid; Case-Control Studies; Cerebrum; Choline; Cognition; Cognition Disorders; Creat

2016
[Hemichorea with Contralateral High Signal Intensity Putaminal Lesion on T1-Weighted Images in Non-Ketotic Hyperglycemia].
    Fortschritte der Neurologie-Psychiatrie, 2016, Volume: 84, Issue:4

    Topics: Aspartic Acid; Choline; Chorea; Creatine; Diabetes Complications; Diabetes Mellitus, Type 2; Diffusi

2016
Evaluation of Biochemical Composition of Vitreous of Eyes of Diabetic Patients Using Proton Magnetic Resonance Spectroscopy.
    Current eye research, 2017, Volume: 42, Issue:5

    Topics: Adult; Biomarkers; Creatine; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Fluorescein An

2017
Risk for metabolic syndrome predisposes to alterations in the thalamic metabolism.
    Metabolic brain disease, 2008, Volume: 23, Issue:3

    Topics: Adult; Anthropometry; Aspartic Acid; Blood Glucose; Choline; Creatine; Diabetes Mellitus, Type 2; Hu

2008
MR spectroscopy of cerebral white matter in type 2 diabetes; no association with clinical variables and cognitive performance.
    Neuroradiology, 2010, Volume: 52, Issue:2

    Topics: Aged; Aged, 80 and over; Aspartic Acid; Brain; Choline; Cognition; Cognition Disorders; Creatine; Di

2010
Derivation and validation of a new cardiovascular risk score for people with type 2 diabetes: the new zealand diabetes cohort study.
    Diabetes care, 2010, Volume: 33, Issue:6

    Topics: Albuminuria; Cardiovascular Diseases; Cohort Studies; Creatine; Diabetes Mellitus, Type 2; Female; G

2010
Correlations of creatine and six related pyrimidine metabolites and diabetic nephropathy in Chinese type 2 diabetic patients.
    Clinical biochemistry, 2010, Volume: 43, Issue:12

    Topics: Aged; Chromatography, High Pressure Liquid; Creatine; Cytidine; Cytosine; Deoxyuridine; Diabetes Mel

2010
A metabonomic comparison of urinary changes in Zucker and GK rats.
    Journal of biomedicine & biotechnology, 2010, Volume: 2010

    Topics: Acids, Acyclic; Animals; Biomarkers; Creatine; Diabetes Mellitus, Type 2; Dimethylamines; Disease Mo

2010
Identifying additional patients with diabetic nephropathy using the UK primary care initiative.
    Diabetic medicine : a journal of the British Diabetic Association, 2010, Volume: 27, Issue:12

    Topics: Creatine; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progre

2010
Systemic soluble tumor necrosis factor receptors 1 and 2 are associated with severity of diabetic retinopathy in Hispanics.
    Ophthalmology, 2012, Volume: 119, Issue:5

    Topics: Blood Pressure; Cohort Studies; Creatine; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabet

2012
Diabetic nephropathy.
    The New England journal of medicine, 2002, Sep-19, Volume: 347, Issue:12

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihype

2002
Independent impact of glycemia and blood pressure in albuminuria on high-risk subjects for metabolic syndrome.
    Clinical nephrology, 2004, Volume: 61, Issue:6

    Topics: Aged; Albuminuria; Analysis of Variance; Brazil; Chi-Square Distribution; Creatine; Diabetes Mellitu

2004
Renal accumulation and clearance of advanced glycation end-products in type 2 diabetic nephropathy: effect of angiotensin-converting enzyme and vasopeptidase inhibition.
    Diabetologia, 2005, Volume: 48, Issue:8

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Ascorbic Acid; Blood Glucose; Chromatography, Hig

2005
Effect of angiotensin blockade on the association between albuminuria and peripheral arterial disease in elderly Taiwanese patients with type 2 diabetes mellitus.
    Circulation journal : official journal of the Japanese Circulation Society, 2005, Volume: 69, Issue:8

    Topics: Aged; Albumins; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme

2005
Creatine supplementation increases soleus muscle creatine content and lowers the insulinogenic index in an animal model of inherited type 2 diabetes.
    International journal of molecular medicine, 2006, Volume: 17, Issue:6

    Topics: Adenosine Triphosphate; Animals; Blood Glucose; Body Weight; Creatine; Diabetes Mellitus, Type 2; Di

2006
Rate of decline of GFR and progression of vascular disease in type 2 diabetic patients with diabetic or vascular nephropathy during the last three years before starting dialysis therapy.
    Kidney & blood pressure research, 2006, Volume: 29, Issue:5

    Topics: Aged; Blood Pressure; Cholesterol; Creatine; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabe

2006
Measurement of brain metabolites in patients with type 2 diabetes and major depression using proton magnetic resonance spectroscopy.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2007, Volume: 32, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Aspartic Acid; Brain Chemistry; Choline; Creatine; Depressive Disord

2007
Effects of KIOM-79 on hyperglycemia and diabetic nephropathy in type 2 diabetic Goto-Kakizaki rats.
    Journal of ethnopharmacology, 2007, May-04, Volume: 111, Issue:2

    Topics: Administration, Oral; Animals; Blood Glucose; Collagen Type IV; Creatine; Diabetes Mellitus, Experim

2007
Proinflammatory and proapoptotic effects of methylglyoxal on neutrophils from patients with type 2 diabetes mellitus.
    Clinical biochemistry, 2007, Volume: 40, Issue:16-17

    Topics: Aged; Albuminuria; Anti-Inflammatory Agents; Apoptosis; Blood Glucose; Caspase 3; Creatine; Cytokine

2007
Prevalence and predictors of cardiac hypertrophy and dysfunction in patients with Type 2 diabetes.
    Clinical science (London, England : 1979), 2008, Volume: 114, Issue:4

    Topics: Aging; Analysis of Variance; Antihypertensive Agents; Cardiomegaly; Creatine; Cross-Sectional Studie

2008
Assessment of the metabolic profile in Type 2 diabetes mellitus and hypothyroidism through proton MR spectroscopy.
    Magnetic resonance imaging, 2008, Volume: 26, Issue:3

    Topics: Adult; Aspartic Acid; Brain; Choline; Creatine; Diabetes Mellitus, Type 2; Female; Humans; Hypothyro

2008
Case report: diabetic microangiopathic hemolytic anemia and thrombocytopenia with antiphospholipid syndrome.
    The American journal of the medical sciences, 1996, Volume: 311, Issue:3

    Topics: Adult; Anemia, Hemolytic; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Creatine; Diabete

1996
Angiopathy affects circulating endothelin-1 levels in type 2 diabetic patients.
    Acta diabetologica, 1995, Volume: 32, Issue:4

    Topics: Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol; Creatine; Diabetes Mellitus

1995
High prevalence of small LDL particles in non-insulin-dependent diabetic patients with nephropathy.
    Atherosclerosis, 1996, Volume: 123, Issue:1-2

    Topics: Aged; Albuminuria; Apoproteins; Blood Glucose; Body Mass Index; Carrier Proteins; Cholesterol Ester

1996
Evaluation of plasma cystatin C as a marker for glomerular filtration rate in patients with type 2 diabetes.
    Clinical nephrology, 1999, Volume: 52, Issue:6

    Topics: Aged; Biomarkers; Creatine; Cystatin C; Cystatins; Diabetes Mellitus, Type 2; Evaluation Studies as

1999
[Bone complication in diabetes subjects with good metabolic control and without longterm complications: certain problems. Part II. Basal parameters of bone turnover].
    Przeglad lekarski, 2001, Volume: 58, Issue:6

    Topics: Alkaline Phosphatase; Bone Resorption; Creatine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type

2001
Clinical test of renal guanidinoacetic acid metabolism by oral citrulline and creatine loading.
    Clinica chimica acta; international journal of clinical chemistry, 1992, Jul-31, Volume: 209, Issue:1-2

    Topics: 17-Ketosteroids; Amidinotransferases; Animals; Chronic Disease; Citrulline; Creatine; Diabetes Melli

1992
Serum type IV collagen concentrations in diabetic patients with microangiopathy as determined by enzyme immunoassay with monoclonal antibodies.
    Diabetes, 1990, Volume: 39, Issue:8

    Topics: Aged; Antibodies, Monoclonal; Beta-Globulins; Blood Urea Nitrogen; Collagen; Creatine; Diabetes Mell

1990
Variability of albumin excretion in diabetes.
    The Netherlands journal of medicine, 1989, Volume: 34, Issue:5-6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuminuria; Creatine; Data Collection; Diabetes Mellitu

1989
[Early detection of nephroangiopathy in patients with diabetes mellitus and approaches to its correction].
    Terapevticheskii arkhiv, 1989, Volume: 61, Issue:6

    Topics: Creatine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Neph

1989